Amerimmune Publications

Towards standardizing basophil identification by flow cytometry

Sonder, S.U., Plassmeyer, M., Loizou, D., and Alpan, O. (2023). Towards standardizing basophil identification by flow cytometry. Front. Allergy 4, 1133378. 10.3389/falgy.2023.1133378.

Towards an FDA-cleared basophil activation test

Alpan, O., Wasserman, R.L., Kim, T., Darter, A., Shah, A., Jones, D., McNeil, D., Li, H., Ispas, L., Rathkopf, M., et al. (2023). Towards an FDA-cleared basophil activation test. Front. Allergy 3, 1009437. 10.3389/falgy.2022.1009437.

Caspases and therapeutic potential of inhibitors in moderate-severe SARS-CoV-2 infection and long COVID

Plassmeyer, M., Alpan, O., Corley, M.J., Premeaux, T.A., Lillard, K., Coatney, P., Vaziri, T., Michalsky, S., Pang, A.P.S., Bukhari, Z., et al. (2022). Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID. Allergy 77, 118–129. 10.1111/all.14907.

Validation of inducible basophil biomarkers: Time, temperature and transportation

Kim, T., Yu, J., Li, H., Scarupa, M., Wasserman, R.L., Economides, A., White, M., Ward, C., Shah, A., Jones, D., et al. (2021). Validation of inducible basophil biomarkers: Time, temperature and transportation. Cytometry Part B: Clinical Cytometry 100, 632–644. https://doi.org/10.1002/cyto.b.21991.

CRS with Nasal Polyposis; Distinguishing Characteristics Through Immune-Phenotyping

Kumar, A., Alpan, O., Rubinstein, M., Black, K., Soltany, M., Lee, P., Doyle, D., McKenzie, B., Murray, R., Kim, W., et al. (2020). CRS with Nasal Polyposis; Distinguishing Characteristics Through Immune-Phenotyping. Journal of Allergy and Clinical Immunology 145, AB150. 10.1016/j.jaci.2019.12.483.

Impact of immune work‐up on outcomes and the cost of care in patients with Chronic Rhinosinusitis

Alpan, O., Loizou, D., Santos, I., Ness, B., and Plandowski, J. (2019). Impact of immune work-up on outcomes and the cost of care in patients with Chronic Rhinosinusitis. Allergy 74, 1802–1805. https://doi.org/10.1111/all.13793.

Improved panels for clinical immune phenotyping: Utilization of the violet laser.

Ryherd, M., Plassmeyer, M., Alexander, C., Eugenio, I., Kleschenko, Y., Badger, A., Gupta, R., Alpan, O., and Sønder, S.U. (2018). Improved panels for clinical immune phenotyping: Utilization of the violet laser: UTILIZATION OF THE VIOLET LASER FOR IMMUNE PHENOTYPING. Cytometry 94, 827–835. 10.1002/cyto.b.21532.

Idiopathic Angioedema: Difficult Cases and Uncommon Findings

Noonan, L.E., Alpan, O., Loizou, D., and Goker-Alpan, O. (2016). Idiopathic Angioedema: Difficult Cases and Uncommon Findings. Journal of Allergy and Clinical Immunology 137, AB80. 10.1016/j.jaci.2015.12.392.

Randomized trial of peanut consumption in infants at risk for peanut allergy

Noonan, L., and Alpan, O. (2015). Peanut consumption in infants at risk for peanut allergy. N Engl J Med 372, 2163.

A pilot study of omalizumab in eosinophilic esophagitis.

Loizou, D., Enav, B., Komlodi-Pasztor, E., Hider, P., Kim-Chang, J., Noonan, L., Taber, T., Kaushal, S., Limgala, R., Brown, M., et al. (2015). A Pilot Study of Omalizumab in Eosinophilic Esophagitis. PLoS ONE 10, e0113483. 10.1371/journal.pone.0113483.

Diffuse Cutaneous Mastocytosis, Bullous Variant, Presenting in a Six-Month-Old Infant

Kinneman, L., Molloy, B., Nguyen, V., Loizou, D., Silverman, R., Mensah-Bonsu, N., Enav, B., Johal, J., Plassmeyer, M., Ryherd, M., et al. (2014). Diffuse Cutaneous Mastocytosis, Bullous Variant, Presenting in a Six-Month-Old Infant. The Journal of Allergy and Clinical Immunology: In Practice 2, 341–342. https://doi.org/10.1016/j.jaip.2014.02.016.

High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.

Busse, W., Spector, S., Rosén, K., Wang, Y., and Alpan, O. (2013). High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects. Journal of Allergy and Clinical Immunology 132, 485-486.e11. 10.1016/j.jaci.2013.02.032.

Initial Presentation of Severe Neutropenia Mimicking Atopic Dermatitis

Noonan, L.E., Alpan, O., Loizou, D., Brown, M., Ryherd, M., and Plassmeyer, M. (2013). Initial Presentation of Severe Neutropenia Mimicking Atopic Dermatitis. Journal of Allergy and Clinical Immunology 131, AB103. 10.1016/j.jaci.2012.12.1037.

Normal B Cell Subpopulations in the Pediatric Age Groups and Adults

Plassmeyer, M., Ryherd, M., Brown, M., Gupta, R., Lacbawan, L., and Alpan, O. (2013). Normal B Cell Subpopulations in the Pediatric Age Groups and Adults. Journal of Allergy and Clinical Immunology 131, AB67. 10.1016/j.jaci.2012.12.904.

Oral immunotherapy for egg allergy in children.

Alpan, O., Miehlke, S., and Straumann, A. (2012). Oral Immunotherapy for Egg Allergy in Children. New England Journal of Medicine 367, 1471–1473. 10.1056/NEJMc1209949.

Collaboration Publications

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

Patterson, B.K., Seethamraju, H., Dhody, K., Corley, M.J., Kazempour, K., Lalezari, J., Pang, A.P.S., Sugai, C., Mahyari, E., Francisco, E.B., et al. (2021). CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. International Journal of Infectious Diseases 103, 25–32. 10.1016/j.ijid.2020.10.101.

Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19

Mikail Dogan, Lina Kozhaya, Lindsey Placek, Courtney L. Gunter, Mesut Yigit, Rachel Hardy, Matt Plassmeyer, Paige Coatney, Kimberleigh Lillard, Zaheer Bukhari, et al. (2020). Novel SARS-CoV-2 specific antibody and neutralization assays reveal wide range of humoral immune response during COVID-19. medRxiv, 2020.07.07.20148106. 10.1101/2020.07.07.20148106.

Inflammasome Activation and Pyroptosis in Lymphopenic COVID-19 Liver Patients Alexander

Kroemer, A., Khan, K., Plassmeyer, M., Alpan, O., Haseeb, M.A., Gupta, R., and Fishbein, T.M. (2020). Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19. Journal of Hepatology 73, 1258–1262. 10.1016/j.jhep.2020.06.034.

Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice

Santos, A., Alpan, O., and Hoffmann, H.J.R. (2020). Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice (Preprints) 10.22541/au.159493194.42634850.

Clinical utility of Basophil and B-cell biomarkers for monitoring disease activity in food allergy and food oral immunotherapy

Theodore Kim, Richard L. Wasserman, Oral Alpan, Atul Shah, and Douglas Jones (2020). Clinical utility of Basophil and B-cell biomarkers for monitoring disease activity in food allergy and food oral immunotherapy. medRxiv, 2020.01.15.20017541. 10.1101/2020.01.15.20017541.

Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2018 Conference Workshops

Czechowska, K., Lannigan, J., Wang, L., Arcidiacono, J., Ashhurst, T.M., Barnard, R.M., Bauer, S., Bispo, C., Bonilla, D.L., Brinkman, R.R., et al. (2019). Cyt‐Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2018 Conference Workshops. Cytometry 95, 598–644. 10.1002/cyto.a.23777.

Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta

Limgala, R.P., Jennelle, T., Plassmeyer, M., Boutin, M., Lavoie, P., Abaoui, M., Auray-Blais, C., Nedd, K., Alpan, O., and Goker-Alpan, O. Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta.

A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.

Lovell, D.J., Dare, J.A., Francis-Sedlak, M., Ball, J., LaMoreaux, B.D., Von Scheven, E., Reinhardt, A., Jerath, R., Alpan, O., Gupta, R., et al. (2018). A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis. Pediatr Rheumatol 16, 41. 10.1186/s12969-018-0260-y.

Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease.

Limgala, R.P., Ioanou, C., Plassmeyer, M., Ryherd, M., Kozhaya, L., Austin, L., Abidoglu, C., Unutmaz, D., Alpan, O., and Goker-Alpan, O. (2016). Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease. PLoS ONE 11, e0168135. 10.1371/journal.pone.0168135.

Enzyme replacement therapy reverses B lymphocyte and dendritic cell dysregulations in patients with Gaucher Disease.

Limgala, R.P., Jani, C., Ioanou, C., Alpan, O., and Goker-Alpan, O. (2018). Enzyme replacement therapy reverses B lymphocyte and dendritic cell dysregulations in patients with Gaucher Disease. Blood Cells, Molecules, and Diseases 68, 81–85. https://doi.org/10.1016/j.bcmd.2016.10.015.

Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease.

Sønder, S.U., Limgala, R.P., Ivanova, M.M., Ioanou, C., Plassmeyer, M., Marti, G.E., Alpan, O., and Goker-Alpan, O. (2016). Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease. Blood Cells, Molecules, and Diseases 59, 8–15. https://doi.org/10.1016/j.bcmd.2016.02.003.

Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis.

Safroneeva, E., Straumann, A., Coslovsky, M., Zwahlen, M., Kuehni, C.E., Panczak, R., Haas, N.A., Alexander, J.A., Dellon, E.S., Gonsalves, N., et al. (2016). Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. Gastroenterology 150, 581-590.e4. 10.1053/j.gastro.2015.11.004.

Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity.

Safroneeva, E., Coslovsky, M., Kuehni, C.E., Zwahlen, M., Haas, N.A., Panczak, R., Taft, T.H., Hirano, I., Dellon, E.S., Gonsalves, N., et al. (2015). Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. Aliment Pharmacol Ther 42, 1000–1010. 10.1111/apt.13370.

How do gastroenterologists assess overall activity of eosinophilic esophagitis in adult patients?

Schoepfer, A.M., Panczak, R., Zwahlen, M., Kuehni, C.E., Coslovsky, M., Maurer, E., Haas, N.A., Alexander, J.A., Dellon, E.S., Gonsalves, N., et al. (2015). How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients? Official journal of the American College of Gastroenterology | ACG 110.

Effect of time of initiating enzyme replacement therapy on immune dysfunction in patients with Gaucher disease

Goker-Alpan, O., Limgala, R.P., Ioanou, C., Plassmeyer, M., Ryherd, M., Austin, L., and Alpan, O. (2015). Effect of time of initiating enzyme replacement therapy on immune dysfunction in patients with Gaucher disease. Molecular Genetics and Metabolism 114, S48. https://doi.org/10.1016/j.ymgme.2014.12.094.

Gastrointestinal manifestations of immune dysregulation and Gaucher disease: Mesenteric lymphadenopathy and enteropathy with profound T cell defects

Limgala, R.P., Abrahamov, A., Hadas-Halpern, I., Ryherd, M., Austin, L., Plassmeyer, M., Brown, M., Alpan, O., Elstein, D., Zimran, A., et al. (2015). Gastrointestinal manifestations of immune dysregulation and Gaucher disease: Mesenteric lymphadenopathy and enteropathy with profound T cell defects. Molecular Genetics and Metabolism 114, S73. https://doi.org/10.1016/j.ymgme.2014.12.157.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.

1. Saini, S.S., Bindslev-Jensen, C., Maurer, M., Grob, J.-J., Bülbül Baskan, E., Bradley, M.S., Canvin, J., Rahmaoui, A., Georgiou, P., Alpan, O., et al. (2015). Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study. Journal of Investigative Dermatology 135, 925. 10.1038/jid.2014.512.

Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis.

Rothenberg, M.E., Wen, T., Greenberg, A., Alpan, O., Enav, B., Hirano, I., Nadeau, K., Kaiser, S., Peters, T., Perez, A., et al. (2015). Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. Journal of Allergy and Clinical Immunology 135, 500–507. 10.1016/j.jaci.2014.07.049.

Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis.

Schoepfer, A.M., Straumann, A., Panczak, R., Coslovsky, M., Kuehni, C.E., Maurer, E., Haas, N.A., Romero, Y., Hirano, I., Alexander, J.A., et al. (2014). Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis. Gastroenterology 147, 1255-1266.e21. 10.1053/j.gastro.2014.08.028.

Understanding the Role of Familial Allergies in Children with Eosinophilic Esophagitis

Awadalla, N., Alpan, O., Loizou, D., and Hiremath, G. (2013). Understanding the Role of Familial Allergies in Children with Eosinophilic Esophagitis. Journal of Allergy and Clinical Immunology 131, AB178. 10.1016/j.jaci.2012.12.1300.